8-K: Xilio Therapeutics Inks Global Licensing Deal with Gilead, Secures $11.3 Million in Private Placement

Xilio Therapeutics has entered into an exclusive licensing agreement with Gilead for its tumor-activated IL-12 program and secured $11.3 million through a private placement, while also announcing a strategic portfolio reprioritization.

Summary

• Xilio Therapeutics has granted Gilead Sciences an exclusive global license to develop and commercialize XTX301, a tumor-activated IL-12, and other related molecules.
• Xilio will receive $43.5 million upfront, including $30 million in cash and a $13.5 million equity investment from Gilead at $1.97 per share.
• Xilio is eligible for up to $604 million in additional contingent payments, including further equity investments, a $75 million transition fee, and development, regulatory, and sales-based milestones.
• Xilio will conduct clinical development for XTX301 through an initial Phase 2 dose expansion, after which Gilead can elect to take over development and commercialization.
• Xilio has also secured $11.3 million in a private placement by selling shares at $0.64 per share and prefunded warrants at $0.6399 per warrant.
• The company plans to use the proceeds for working capital and general corporate purposes.
• Xilio is reprioritizing its portfolio to focus on XTX301 and XTX101, discontinuing further investment in XTX202 as a monotherapy, and reducing its workforce by 15 employees (approximately 21%).
• The company estimates one-time costs of approximately $1 million related to the workforce reduction.
• Xilio estimates its cash and cash equivalents were $44.7 million as of December 31, 2023.
• The company anticipates its cash runway will extend into the second quarter of 2025.

Sentiment

Score: 8

Explanation: The document is largely positive due to the significant licensing deal with Gilead and the successful private placement. The strategic reprioritization and workforce reduction are necessary steps to focus resources, but the overall tone is optimistic about the company's future prospects.

Positives

• The licensing agreement with Gilead provides significant upfront funding and potential for substantial future payments.
• The private placement provides additional capital to support operations and development.
• The strategic portfolio reprioritization focuses resources on the most promising clinical programs.
• The company has repaid all amounts outstanding under its loan agreement with Pacific Western Bank.
• The company has a clear plan to extend its cash runway into the second quarter of 2025.

Negatives

• The company is discontinuing further investment in XTX202 as a monotherapy.
• The company is reducing its workforce by 15 employees, which may impact morale and productivity.
• The company will incur one-time costs of approximately $1 million related to the workforce reduction.

Risks

• The company's ability to achieve milestones and receive contingent payments from Gilead is subject to development, regulatory, and sales-based factors.
• The company's ability to successfully develop and commercialize its product candidates is subject to clinical trial risks and regulatory approvals.
• The company's cash runway is dependent on its current operating plans and may be affected by unforeseen circumstances.
• The company's strategic portfolio reprioritization may not yield the desired results.
• The company's workforce reduction may negatively impact its operations and development timelines.

Future Outlook

The company anticipates that its cash and cash equivalents, along with the upfront payment from Gilead, proceeds from the private placement, and cost savings, will be sufficient to fund its operating expenses and capital expenditure requirements into the second quarter of 2025.

Management Comments

• Gileads confidence in our tumor-activated technology, combined with their deep expertise in developing and commercializing novel immuno-oncology products, will enable us to accelerate and expand the development of XTX301, our tumor-activated IL-12.
• We believe our decision to reprioritize Xilios clinicaland research-stage investments and resources best positions us to achieve near-term clinical milestones and value-drivers while seeking to deliver on the long-term promise of our differentiated research platform and capabilities.

Industry Context

This announcement reflects a growing trend in the biotech industry of companies focusing on strategic partnerships and prioritizing their pipelines to maximize value and extend cash runways. The licensing deal with Gilead highlights the increasing interest in tumor-activated immuno-oncology therapies.

Comparison to Industry Standards

• The upfront payment of $43.5 million and potential for $604 million in milestones is a significant deal for a company of Xilio's size, comparable to other licensing agreements in the immuno-oncology space.
• The private placement of $11.3 million is a common method for biotech companies to raise capital, especially after a major partnership announcement.
• The strategic portfolio reprioritization and workforce reduction are also common strategies for biotech companies to manage resources and extend cash runways, similar to actions taken by companies like Agenus and Gritstone Bio in recent times.
• The focus on tumor-activated therapies aligns with the industry's push for more targeted and less toxic cancer treatments, similar to the approaches taken by companies like BioNTech and Moderna with their mRNA-based therapies.

Stakeholder Impact

• Shareholders will benefit from the increased funding and potential for future growth.
• Employees will be impacted by the workforce reduction, with 15 employees losing their jobs.
• Customers (patients) may benefit from the development of new cancer therapies.
• Suppliers and creditors may be impacted by the company's strategic portfolio reprioritization.

Next Steps

• Xilio will continue clinical development of XTX301 through Phase 2 dose expansion.
• Gilead may elect to transition responsibilities for the development and commercialization of XTX301.
• Xilio will explore strategic opportunities to continue to develop XTX202 in combination with other agents.
• Xilio will advance its research platform to develop bispecific and cell engager molecules.
• The company will file a registration statement with the SEC for the resale of securities sold in the private placement.

Key Dates

Keywords

Xilio Therapeutics, Gilead Sciences, XTX301, IL-12, Immuno-oncology, Private Placement, Licensing Agreement, XTX101, XTX202, Clinical Development, Tumor-Activated, Biotech, Capital Raise